The purpose of this revision of the Quality Review of Documents human product information is to implement the new provisions from the pharmacovigilance legislation. This consultation aims to present the proposals to be included in the summary of product characteristics and package leaflet regarding the location of the black symbol and the location and wording of the explanatory statement for additional monitoring and of the standardised text to encourage the reporting of adverse reactions.
Go to Source

This entry was posted on Monday, July 16th, 2012 at 12:30 pm and is filed under European Medicines Agency. You can follow any responses to this entry through the RSS 2.0 feed. You can skip to the end and leave a response. Pinging is currently not allowed.